Stephen V Liu: Real-world 5-year survival with first line pembrolizumab in PD-L1 high NSCLC
Stephen V Liu, Associate Professor of Medicine at Georgetown University, shared a post on X:
“Real-world 5-year survival with 1L pembrolizumab in PD-L1 high NSCLC in current issue of Clinical Lung Cancer. With median f/u 60.5m, OS 19.2m, 5y OS rate 25.1%. Also noted 33% received subsequent therapy.”
Authors: Vamsidhar Velcheti, Yu-Han Kao, Diana Chirovsky, Ana Tablante Nunes and Stephen V. Liu.
Luis E. Raez shared the above post on X, adding:
“We learn that 25% of our pdl-1 high patients can live more than 5 years compare with 5% we use to get with chemo alone before there is progress, more needs to be done.”
Stephen V Liu is an Associate Professor of Medicine at Georgetown University, where he holds the positions of Director of Thoracic Oncology and Head of Developmental Therapeutics at the Georgetown Lombardi Comprehensive Cancer Center. As a board-certified medical oncologist specializing in lung cancer and drug development, Dr. Liu is known for his expertise in advanced thoracic malignancies.
His research focuses on novel therapeutic agents and innovative combinations to improve treatment outcomes for patients with lung cancer. Dr. Liu has received multiple teaching awards and actively engages in post-graduate education initiatives. Furthermore, he co-hosts the official podcast of the International Association for the Study of Lung Cancer (IASLC), “Lung Cancer Considered”.
Dr. Luis E. Raez is the Medical Director and Chief Scientific Officer at Memorial Cancer Institute, part of Memorial Healthcare System. He specializes in treating lung and head and neck cancers and leads the Thoracic Oncology Program as Director. Dr. Raez is also a clinical professor of medicine at Florida International University (FIU), a research professor at Florida Atlantic University (FAU), and a visiting professor of medicine at Cayetano Heredia University (UPCH) in Peru.
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023